Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Mesothelioma 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 6Nivolumab 3tislelizumab 2budigalimab 2Ipilimumab 2Depsipeptides 2Decitabine 2venetoclax 1talazoparib 1spartalizumab 1sargramostim 1rovalpituzumab tesirine 1regorafenib 1poly ICLC 1iodixanol 1epacadostat 1entinostat 1durvalumab 1cemiplimab 1avelumab 1atezolizumab 1alvocidib 1Tomography, Optical Coherence 1Tissue Banks 1Tablets 1Radiosurgery 1Radiofrequency Ablation 1Paclitaxel 1Iohexol 1Interferon-gamma 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × poly ICLC × Other solid neoplasm × Clear all
NCT02661100 2016-12-07

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Case Comprehensive Cancer Center

Phase 1/2 Withdrawn
DermatologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡